doi: 10.1161/hc0402.102951
(Circulation. 2002;105:483.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
Ubiquitin-Proteasome Pathway as a New Target for the Prevention of Restenosis
From Medizinische Klinik und Poliklinik (Kardiologie, Angiologie, Pneumologie), Charité, Campus Mitte, Humboldt-Universität zu Berlin, Germany (S.M., M.L., W.R., C.G., I.P., G.B., K.S.); Institut für Biochemie, Charité, Humboldt-Universität zu Berlin, Germany (P.-M.K.); and Schering AG, Berlin, Germany (P.M.).
Correspondence to Karl Stangl, MD, Medizinische Klinik und Poliklinik (Kardiologie, Angiologie, Pneumologie), Charité, Campus Mitte, Schumannstrasse 20/21, D-10117 Berlin, Germany. E-mail karl.stangl{at}charite.de
Background— The ubiquitin-proteasome system is the major intracellular protein degradation pathway in eucaryotic cells. It regulates central mediators of proliferation, inflammation, and apoptosis that are fundamental pathomechanisms in the development of vascular restenosis.
Methods and Results— Effects of proteasome inhibition on neointima formation were studied in a balloon injury model in the rat carotid artery. Local application of the proteasome inhibitor MG132 (1 mmol/L) resulted in significant inhibition of intimal hyperplasia, that is, by 74% (P=0.008). This effect was accompanied by decreased proliferation, reduced infiltration of macrophages, and prolonged apoptosis, as determined by immunohistochemical and TUNEL analyses. Functional effects of proteasome inhibition on proliferation, activation of nuclear factor kappa B, and apoptosis were further characterized in rat primary vascular smooth muscle cells. MG132 dose-dependently inhibited vascular smooth muscle cell proliferation with 50% inhibition at 10 µmol/L. TNF
-induced degradation of I
B and ß was blocked, and activation of nuclear factor kappa B was suppressed in a concentration-dependent manner in bandshift assays. Moreover, proteasome inhibition (1 to 50 µmol/L MG132) induced apoptotic cell death up to 80%, as confirmed by DNA/Histone-ELISA and TUNEL-FACS analysis. Specificity of proteasome inhibition was shown by accumulation of multiubiquitinylated proteins and accumulation of specific proteasomal substrates.
Conclusions— These proof-of-principle experiments demonstrate that inhibition of the ubiquitin-proteasome system effectively reduces neointima formation in vivo, which corresponds to strong antiproliferative, anti-inflammatory, and proapoptotic effects in vitro and in vivo. Our data suggest the ubiquitin-proteasome system as a new target in the prevention of vascular restenosis.
Key Words: restenosis • apoptosis • inhibitors • inflammation
This article has been cited by other articles:
 |
|
 |
|
  K. Stangl and V. Stangl The ubiquitin proteasome pathway and endothelial (dys)function Cardiovasc Res, October 13, 2009; (2009) cvp315v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Dreger, K. Westphal, N. Wilck, G. Baumann, V. Stangl, K. Stangl, and S. Meiners Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2 Cardiovasc Res, September 4, 2009; (2009) cvp279v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Herrmann, S. M. Soares, L. O. Lerman, and A. Lerman Potential Role of the Ubiquitin-Proteasome System in Atherosclerosis: Aspects of a Protein Quality Disease J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2003 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takami, H. Nakagami, R. Morishita, T. Katsuya, H. Hayashi, M. Mori, H. Koriyama, Y. Baba, O. Yasuda, H. Rakugi, et al. Potential Role of CYLD (Cylindromatosis) as a Deubiquitinating Enzyme in Vascular Cells Am. J. Pathol., March 1, 2008; 172(3): 818 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meiners, H. Dreger, M. Fechner, S. Bieler, W. Rother, C. Gunther, G. Baumann, V. Stangl, and K. Stangl Suppression of Cardiomyocyte Hypertrophy by Inhibition of the Ubiquitin-Proteasome System Hypertension, February 1, 2008; 51(2): 302 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukai Targeting Proteasome Worsens Atherosclerosis Circ. Res., October 26, 2007; 101(9): 859 - 861. [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann, A. M. Saguner, D. Versari, T. E. Peterson, A. Chade, M. Olson, L. O. Lerman, and A. Lerman Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis Circ. Res., October 26, 2007; 101(9): 865 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takami, H. Nakagami, R. Morishita, T. Katsuya, T.-X. Cui, T. Ichikawa, Y. Saito, H. Hayashi, Y. Kikuchi, T. Nishikawa, et al. Ubiquitin Carboxyl-Terminal Hydrolase L1, a Novel Deubiquitinating Enzyme in the Vasculature, Attenuates NF-{kappa}B Activation Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2184 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Versari, J. Herrmann, M. Gossl, D. Mannheim, K. Sattler, F. B. Meyer, L. O. Lerman, and A. Lerman Dysregulation of the Ubiquitin-Proteasome System in Human Carotid Atherosclerosis Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2132 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Giordano, R. Avellino, P. Ferraro, S. Romano, N. Corcione, and M. F. Romano Rapamycin antagonizes NF-{kappa}B nuclear translocation activated by TNF-{alpha} in primary vascular smooth muscle cells and enhances apoptosis Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2459 - H2465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Zolk, C. Schenke, and A. Sarikas The ubiquitin-proteasome system: Focus on the heart Cardiovasc Res, June 1, 2006; 70(3): 410 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sandbo, Y. Qin, S. Taurin, D. K. Hogarth, B. Kreutz, and N. O. Dulin Regulation of Serum Response Factor-Dependent Gene Expression by Proteasome Inhibitors Mol. Pharmacol., March 1, 2005; 67(3): 789 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Martinet, M. De Bie, D. M. Schrijvers, G. R.Y. De Meyer, A. G. Herman, and M. M. Kockx 7-Ketocholesterol Induces Protein Ubiquitination, Myelin Figure Formation, and Light Chain 3 Processing in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2296 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Toutouzas, A. Colombo, and C. Stefanadis Inflammation and restenosis after percutaneous coronary interventions Eur. Heart J., October 1, 2004; 25(19): 1679 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meiners, B. Hocher, A. Weller, M. Laule, V. Stangl, C. Guenther, M. Godes, A. Mrozikiewicz, G. Baumann, and K. Stangl Downregulation of Matrix Metalloproteinases and Collagens and Suppression of Cardiac Fibrosis by Inhibition of the Proteasome Hypertension, October 1, 2004; 44(4): 471 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Dong, J. Liu, H. Zheng, J. W. Glasford, W. Huang, Q. H. Chen, N. R. Harden, F. Li, A. M. Gerdes, and X. Wang In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1417 - H1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Park, H.-S. Kim, H.-M. Yang, K.-W. Park, S.-W. Youn, S.-I. Jeon, D.-H. Kim, B.-K. Koo, I.-H. Chae, D.-J. Choi, et al. Thalidomide as a Potent Inhibitor of Neointimal Hyperplasia After Balloon Injury in Rat Carotid Artery Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 885 - 891. [Abstract] [Full Text]
|
|
|
|
|
|
J. Herrmann, A. Ciechanover, L. O Lerman, and A. Lerman The ubiquitin-proteasome system in cardiovascular diseases--a hypothesis extended Cardiovasc Res, January 1, 2004; 61(1): 11 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Taylor and C. A. McNamara Regulation of Vascular Smooth Muscle Cell Growth: Targeting the Final Common Pathway Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1717 - 1720. [Full Text] [PDF]
|
|
|
|
|
|
A. R. Chade, M. Rodriguez-Porcel, J. P. Grande, X. Zhu, V. Sica, C. Napoli, T. Sawamura, S. C. Textor, A. Lerman, and L. O. Lerman Mechanisms of Renal Structural Alterations in Combined Hypercholesterolemia and Renal Artery Stenosis Arterioscler Thromb Vasc Biol, July 1, 2003; 23(7): 1295 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meiners, D. Heyken, A. Weller, A. Ludwig, K. Stangl, P.-M. Kloetzel, and E. Kruger Inhibition of Proteasome Activity Induces Concerted Expression of Proteasome Genes and de Novo Formation of Mammalian Proteasomes J. Biol. Chem., June 6, 2003; 278(24): 21517 - 21525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patterson and D. Cyr Welcome to the Machine: A Cardiologist's Introduction to Protein Folding and Degradation Circulation, November 19, 2002; 106(21): 2741 - 2746. [Full Text] [PDF]
|
|
|
|
|
|
E. T.H. Yeh Ubiquitin, Proteasome, and Restenosis: A Brave New World for Cardiovascular Research Circulation, January 29, 2002; 105(4): 408 - 410. [Full Text] [PDF]
|
|